Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Journal Article (Journal Article;Multicenter Study)

PURPOSE: Patients with hormone receptor-negative breast cancer generally do not benefit from endocrine-targeted therapies. However, a subset with androgen receptor (AR) expression is predicted to respond to antiandrogen therapies. This phase II study explored bicalutamide in AR-positive, estrogen receptor (ER), and progesterone receptor (PgR)-negative metastatic breast cancer. EXPERIMENTAL DESIGN: Tumors from patients with ER/PgR-negative advanced breast cancer were tested centrally for AR [immunohistochemistry (IHC) > 10% nuclear staining considered positive]. If either the primary or a metastatic site was positive, patients were eligible to receive the AR antagonist bicalutamide at a dose of 150 mg daily. Clinical benefit rate (CBR), the primary endpoint, was defined as the total number of patients who show a complete response (CR), partial response (PR), or stable disease (SD) > 6 months; secondary endpoints included progression-free survival (PFS) and toxicity. Correlative studies included measurement of circulating endocrine markers and IHC surrogates for basal-like breast cancer. RESULTS: Of 424 patients with ER/PgR-negative breast cancer, 12% tested AR-positive. The 6-month CBR was 19% [95% confidence interval (CI), 7%-39%] for bicalutamide. The median PFS was 12 weeks (95% CI, 11-22 weeks). Bicalutamide was well-tolerated with no grade 4/5 treatment-related adverse events observed. CONCLUSION: AR was expressed in 12% of patients with ER/PgR-negative breast cancer screened for this trial. The CBR of 19% observed with bicalutamide shows proof of principle for the efficacy of minimally toxic androgen blockade in a select group of patients with ER/PgR-negative, AR-positive breast cancer.

Full Text

Duke Authors

Cited Authors

  • Gucalp, A; Tolaney, S; Isakoff, SJ; Ingle, JN; Liu, MC; Carey, LA; Blackwell, K; Rugo, H; Nabell, L; Forero, A; Stearns, V; Doane, AS; Danso, M; Moynahan, ME; Momen, LF; Gonzalez, JM; Akhtar, A; Giri, DD; Patil, S; Feigin, KN; Hudis, CA; Traina, TA; Translational Breast Cancer Research Consortium (TBCRC 011),

Published Date

  • October 1, 2013

Published In

Volume / Issue

  • 19 / 19

Start / End Page

  • 5505 - 5512

PubMed ID

  • 23965901

Pubmed Central ID

  • PMC4086643

Electronic International Standard Serial Number (EISSN)

  • 1557-3265

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-12-3327


  • eng

Conference Location

  • United States